Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 2/20 | 0.41 |
| ▸ | CD274 | Q9NZQ7 | 13/20 | 0.40 |
| ▸ | PDCD1 | Q15116 | 9/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | GYS1 | P13807 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13117746 | 0.86 | FFAR1 (0.43) | FFAR1CD274PDCD1MAOB | |
| SCHEMBL12578349 | 0.86 | FFAR1 (0.44) | FFAR1CD274PDCD1HDAC6MAOB | |
| SCHEMBL2907137 | 0.82 | CD274 (0.38) | CD274PDCD1HDAC6GYS1 | |
| SCHEMBL12578352 | 0.82 | FFAR1 (0.51) | FFAR1CD274PDCD1MAOB | |
| SCHEMBL13117607 | 0.81 | SMN1; SMN2 (0.37) | FFAR1CD274PDCD1 | |
| SCHEMBL12578357 | 0.81 | FFAR1 (0.44) | FFAR1CD274PDCD1HDAC6 | |
| SCHEMBL13117732 | 0.80 | FFAR1 (0.41) | FFAR1CD274PDCD1HDAC6MAOB | |
| SCHEMBL13117745 | 0.80 | CD274 (0.42) | FFAR1CD274PDCD1 | |
| SCHEMBL13117711 | 0.80 | CD274 (0.45) | FFAR1CD274PDCD1 | |
| SCHEMBL12578397 | 0.78 | CD274 (0.41) | FFAR1CD274PDCD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100267775-A1 | OXADIAZOLIDINEDIONE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-10-21 | — | — | US | disclosed |
| US-20100267775-A1 | OXADIAZOLIDINEDIONE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-10-21 | — | — | US | disclosed |
| US-20100267775-A1 | OXADIAZOLIDINEDIONE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-10-21 | — | — | US | disclosed |
| EP-2216330-A1 | OXADIAZOLIDINEDIONE COMPOUND | Astellas Pharma Inc. (JP) | 2010-08-11 | — | — | EP | disclosed |
| EP-2216330-A1 | OXADIAZOLIDINEDIONE COMPOUND | Astellas Pharma Inc. (JP) | 2010-08-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267775-A1 | OXADIAZOLIDINEDIONE COMPOUND | GPR119, GLP1R, GPR4 | FFAR1 38/4885CD274 1333/4885PDCD1 1246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.